Sodium Intake in Chronic Kidney Disease (STICK)
NCT02458248 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 105
Last updated 2021-04-28
Summary
Chronic kidney disease, which affects an estimated 300,000 people in Ireland and over 50 million people in the developed world, is responsible for a considerable burden of premature mortality and morbidity. All patients with chronic kidney disease are recommended low salt diets, i.e. less than a teaspoon of salt per day (which is \<5-6g of salt, which contains \<2-2.3g of sodium). The average intake in the general population is double the recommended intake, between 1-2 teaspoons per day, which is considered 'moderate' intake. In patients with hypertension, reducing from moderate (average) to low intake is associated with a small reduction in blood pressure. However, achieving this low target salt intake is difficult, and can have a negative knock-on effect on other healthy dietary factors and kidney hormones. In addition, there is no convincing research to show that patients with chronic kidney disease and normal blood pressure benefit from low salt intake. In fact, the small amount of research that does exist shows that the change in kidney function is the same in people who consume low salt diets (\<1 teaspoon) and moderate (1-2 teaspoons=average intake) salt diets. Moreover, there are some small studies that report that low-salt diets may increase the risk of death due to heart disease. Given that all patients with chronic kidney impairment are recommended a low-salt diet, it is important that we confirm that this recommendation truly benefits patients. In this randomized controlled trial, we hope to determine whether recommending a low salt intake, compared to average/moderate intake, is associated with a slower rate of decline in kidney function in patients with chronic kidney impairment. The results of this study will provide information to guide future research that will have critical implications for management of patients with chronic kidney disease.
Conditions
- Kidney Diseases
- Renal Insufficiency, Chronic
- Renal Insufficiency
Interventions
- BEHAVIORAL
-
Sodium Reduction
In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
Sponsors & Collaborators
-
Health Research Board, Ireland
collaborator OTHER -
National University of Ireland, Galway, Ireland
collaborator OTHER -
University College Hospital Galway
lead OTHER
Principal Investigators
-
Martin J O'Donnell, MB PhD MRCPI · National University of Ireland, Galway
-
Andrew Smyth, MB PhD · National University of Ireland, Galway
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-03-31
- Primary Completion
- 2020-08-31
- Completion
- 2020-08-31
Countries
- Ireland
Study Locations
More Related Trials
-
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
NCT03236246 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
NCT05653492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD)
NCT01341691 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease
NCT01475760 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease
NCT06071143 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis
NCT00548249 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
NCT06522997 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
NCT01736150 ·Status: COMPLETED ·Phase: PHASE3
-
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
NCT05085275 ·Status: COMPLETED ·Phase: PHASE3
-
Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
NCT04566653 ·Status: COMPLETED
-
KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
NCT02268994 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
NCT00733265 ·Status: COMPLETED ·Phase: PHASE1
-
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE
NCT02258074 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis
NCT00750295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease
NCT01000545 ·Status: UNKNOWN ·Phase: PHASE3
-
Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease
NCT03788252 ·Status: COMPLETED ·Phase: PHASE4
-
Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy
NCT02478242 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
NCT04818216 ·Status: COMPLETED ·Phase: PHASE2
-
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01906489 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
NCT03218501 ·Status: COMPLETED ·Phase: PHASE2
-
PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum
NCT01319578 ·Status: COMPLETED ·Phase: NA
-
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
NCT02229929 ·Status: COMPLETED ·Phase: PHASE2
-
42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
NCT01381094 ·Status: COMPLETED ·Phase: PHASE2
-
Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )
NCT05512988 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
NCT01224028 ·Status: COMPLETED ·Phase: PHASE2